UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

The lancet oncology, 2013-11, Vol.14 (12), p.1233-1242

2013

Link zum Volltext

Verfügbarkeit prüfen

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

The lancet oncology, 2018-03, Vol.19 (3), p.405-415

2018

Link zum Volltext

Verfügbarkeit prüfen

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma

Journal of vascular and interventional radiology, 2017-02, Vol.28 (2), p.254-259

2017

Link zum Volltext

Verfügbarkeit prüfen

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 2020-11, Vol.26 (21), p.5598-5608

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

Clinical cancer research, 2011-12, Vol.17 (24), p.7765-7775

2011

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical genitourinary cancer, 2016-12, Vol.14 (6), p.499-503

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

World journal of urology, 2016-11, Vol.34 (11), p.1567-1573

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Clinical cancer research, 2006-01, Vol.12 (2), p.523-528

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Clinical cancer research, 2005-05, Vol.11 (9), p.3335-3341

2005

Link zum Volltext

Verfügbarkeit prüfen

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

Expert opinion on pharmacotherapy, 2007-12, Vol.8 (17), p.2979-2990

2007

Link zum Volltext

Verfügbarkeit prüfen

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial

Molecular cancer therapeutics, 2006-08, Vol.5 (8), p.2130-2137

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 13 von 13

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(12)

Publikationsform

Artikel
(13)

Sprache

Englisch
(13)

Erscheinungsjahr

n.n

Thema

Humans
(13)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Female
(11)
Male
(11)
Oncology
(11)
Aged
(10)
Middle Aged
(10)
Adult
(7)
Aged, 80 And Over
(5)
Carcinoma, Renal Cell - Drug Therapy
(5)
Carcinoma, Renal Cell - Pathology
(5)
Dose-Response Relationship, Drug
(5)
Kidney Neoplasms - Drug Therapy
(5)
Kidney Neoplasms - Pathology
(5)
Kidney Cancer
(4)
Neoplasms - Drug Therapy
(4)
Renal Cell Carcinoma
(4)
Retrospective Studies
(4)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(4)
Clinical Genitourinary Cancer
(2)
The Lancet Oncology
(2)
Cancer
(1)
Expert Opinion On Pharmacotherapy
(1)
Journal Of Vascular And Interventional Radiology
(1)
Molecular Cancer Therapeutics
(1)
World Journal Of Urology
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial

Aktive Filter

Suchergebnisse filtern